NASDAQ:SBOT - Stellar Biotechnologies Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.52
▼ -1.09 (-16.49%)
Get New Stellar Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBOT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBOT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Stellar Biotechnologies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.52.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Stellar Biotechnologies. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/2/2016Maxim GroupLower Price TargetBuy$49.00 ➝ $28.00N/A
i
Rating by jason mccarthy at Maxim Group
8/11/2016Maxim GroupSet Price TargetBuy$49.00N/A
i
Rating by jason mccarthy at Maxim Group
8/1/2016Maxim GroupBoost Price TargetBuy$49.00 ➝ $119.00N/A
i
Rating by Jason McCarthy at Maxim Group
5/12/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason McCarthy at Maxim Group
(Data available from 2/28/2016 forward)
Stellar Biotechnologies logo
Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.
Read More

Today's Range

Now: $5.52
$5.32
$5.89

50 Day Range

MA: $59,624.23
$4.44
$298,098.00

52 Week Range

Now: $5.52
$0.75
$3.25

Volume

1,662,057 shs

Average Volume

2,949,088 shs

Market Capitalization

$29.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Stellar Biotechnologies?

The following Wall Street analysts have issued research reports on Stellar Biotechnologies in the last year:
View the latest analyst ratings for SBOT.

What is the current price target for Stellar Biotechnologies?

0 Wall Street analysts have set twelve-month price targets for Stellar Biotechnologies in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Stellar Biotechnologies in the next year.
View the latest price targets for SBOT.

What is the current consensus analyst rating for Stellar Biotechnologies?

Stellar Biotechnologies currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SBOT.

What other companies compete with Stellar Biotechnologies?

How do I contact Stellar Biotechnologies' investor relations team?

Stellar Biotechnologies' physical mailing address is 332 EAST SCOTT STREET, PORT HUENEME CA, 93041. The biotechnology company's listed phone number is 805-488-2800 and its investor relations email address is [email protected] The official website for Stellar Biotechnologies is www.stellarbiotechnologies.com.